Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

IntroductionCDK4/6 inhibitors are the first-line treatment for HR+/HER2- advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. To date, there is no thorough comparison among the three approved CDK4/6 inhibitors in terms of their cost-effectiveness.Objectiv...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Shereen Elazzazy, Nour Hisham Al-Ziftawi, Mohamed Izham Mohamed Ibrahim, Salha Bujassoum, Anas Hamad
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	breast cancer palbociclib ribociclib abemaciclib cost-effectiveness
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1413676/full